CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 314 enrolled
Drug / intervention
ctDNA analysis +2 moregenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02418234
NCT02418234N/ACompleted
CompareCT.gov

Frequency and Abundance of T790M Mutation on Circulating Tumor DNA in Patients With Non-small Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment Failure: a Perspective Observational Study

First People's Hospital of Hangzhou·observational·Posted Apr 16, 2015·Updated Mar 12, 2018

In Brief

An observational study evaluating mutation detection, ARMS and ddPCR, and 1 other intervention for Non-small Cell Lung Cancer Stage III and Non-Small-Cell Lung Cancer Metastatic. Completed, enrolled 314 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the frequency and abundance of T790M mutation among the different Clinical modes of EGFR-TKI failure.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer Metastatic
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 16, 2015
Enrollment StartMar 1, 2015
Primary CompletionApr 1, 2016
Study CompletionNov 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.2 years ago

Interventions

mutation detectionother

ARMS and ddPCRother

ctDNA analysisgenetic